Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Christopher, Assaid"'
Autor:
David R. Muccino, Alyn H. Morice, Surinder S. Birring, Peter V. Dicpinigaitis, Ian D. Pavord, Christopher Assaid, Huub Jan Kleijn, Azher Hussain, Carmen La Rosa, Lorcan McGarvey, Jaclyn A. Smith
Publikováno v:
ERJ Open Research, Vol 6, Iss 4 (2020)
Background We present study designs, dose selection and preliminary patient characteristics from two phase 3 clinical trials of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough (RCC) or unexplained chronic cough (UCC). Methods COUG
Externí odkaz:
https://doaj.org/article/797aecd766a64455a4cd9c812cd2c339
Autor:
José R. Arribas, Sanjay Bhagani, Suzana M. Lobo, Ilsiyar Khaertynova, Lourdes Mateu, Roman Fishchuk, William Y. Park, Khetam Hussein, Sei Won Kim, Jade Ghosn, Michelle L. Brown, Ying Zhang, Wei Gao, Christopher Assaid, Jay A. Grobler, Julie Strizki, Mary Vesnesky, Amanda Paschke, Joan R. Butterton, Carisa De Anda
Publikováno v:
NEJM Evidence. 1
Autor:
Angélica, Jayk Bernal, Monica M, Gomes da Silva, Dany B, Musungaie, Evgeniy, Kovalchuk, Antonio, Gonzalez, Virginia, Delos Reyes, Alejandro, Martín-Quirós, Yoseph, Caraco, Angela, Williams-Diaz, Michelle L, Brown, Jiejun, Du, Alison, Pedley, Christopher, Assaid, Julie, Strizki, Jay A, Grobler, Hala H, Shamsuddin, Robert, Tipping, Hong, Wan, Amanda, Paschke, Joan R, Butterton, Matthew G, Johnson, Carisa, De Anda, Mary Beth, Graham
Publikováno v:
The New England journal of medicine. 386(6)
New treatments are needed to reduce the risk of progression of coronavirus disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is active against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).We condu
Autor:
Christopher Assaid, Ian D. Pavord, Lorcan McGarvey, Surinder S. Birring, Alyn H. Morice, Azher Hussain, Carmen La Rosa, Peter V. Dicpinigaitis, David Muccino, Jaclyn A. Smith, Huub Jan Kleijn
Publikováno v:
ERJ Open Research, Vol 6, Iss 4 (2020)
Muccino, D R, Morice, A H, Birring, S S, Dicpinigaitis, P V, Pavord, I D, Assaid, C, Kleijn, H J, Hussain, A, La Rosa, C, McGarvey, L & Smith, J A 2020, ' Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough ', ERJ Open Research, vol. 6, no. 4 . https://doi.org/10.1183/23120541.00284-2020
ERJ Open Research
article-version (VoR) Version of Record
Muccino, D R, Morice, A H, Birring, S S, Dicpinigaitis, P V, Pavord, I D, Assaid, C, Kleijn, H J, Hussain, A, La Rosa, C, McGarvey, L & Smith, J A 2020, ' Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough ', ERJ Open Research, vol. 6, no. 4, 00284 . https://doi.org/10.1183/23120541.00284-2020
Muccino, D R, Morice, A H, Birring, S S, Dicpinigaitis, P V, Pavord, I D, Assaid, C, Kleijn, H J, Hussain, A, La Rosa, C, McGarvey, L & Smith, J A 2020, ' Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough ', ERJ Open Research, vol. 6, no. 4 . https://doi.org/10.1183/23120541.00284-2020
ERJ Open Research
article-version (VoR) Version of Record
Muccino, D R, Morice, A H, Birring, S S, Dicpinigaitis, P V, Pavord, I D, Assaid, C, Kleijn, H J, Hussain, A, La Rosa, C, McGarvey, L & Smith, J A 2020, ' Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough ', ERJ Open Research, vol. 6, no. 4, 00284 . https://doi.org/10.1183/23120541.00284-2020
Background We present study designs, dose selection and preliminary patient characteristics from two phase 3 clinical trials of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough (RCC) or unexplained chronic cough (UCC). Methods COUG
Autor:
David Muccino, Lorcan McGarvey, Ian D. Pavord, Andrew M. Tershakovec, Jacky Smith, Christopher Assaid, Alyn H. Morice, Surinder S. Birring, George Philip, Michael M. Kitt, Peter V. Dicpinigaitis
Publikováno v:
World Allergy Organization Journal, Vol 13, Iss 8, Pp 100203-(2020)
Autor:
David Michelson, Martin R. Farlow, Jeffrey L Cummings, Linda Snow-Adami, Jerry Li, Christopher Assaid, Kerry Budd McMahon, Tiffini Voss, Michael F. Egan, Heather Leibensperger, Samar Froman
Publikováno v:
Alzheimer's & Dementia : Translational Research & Clinical Interventions
Introduction We evaluated the selective M1 muscarinic positive allosteric modulator, MK-7622, as adjunctive cognitive enhancing therapy in individuals with Alzheimer's disease. Methods A randomized, double-blind, proof-of-concept trial was performed.
Autor:
Kathryn M. Connor, David Michelson, Saheeda Jackson, W. Joseph Herring, Joy Yang Ge, Christopher Assaid
Publikováno v:
The Clinical Journal of Pain. 34:37-43
Objectives To evaluate whether orexin receptor antagonism with filorexant provides pain relief in patients with painful diabetic neuropathy (PDN). Methods In this double-blind, placebo-controlled, enriched-enrollment, randomized-withdrawal proof-of-c
Autor:
Christopher Lines, Kerry Budd, Ryan Vargo, Ralph S. Mazenko, Leo Verhagen Metman, Christopher Assaid, W. Joseph Herring, Aaron Ellenbogen
Publikováno v:
Clinical Neuropharmacology. 40:255-260
Objectives Blockade of N-methyl-D-aspartate receptors containing the NR2B subunit has been shown to be therapeutic in animal models of Parkinson disease (PD). However, findings with investigational NR2B receptor antagonists in PD patients have been m
Autor:
Nicole Dupre, Tiffini Voss, David W. Dodick, Sheena K. Aurora, Robert Bachman, Richard B. Lipton, Christopher Assaid, David Michelson, Joy Yang Ge
Publikováno v:
Cephalalgia. 36:887-898
Aim The aim of this trial was to evaluate the efficacy and tolerability of ubrogepant (MK-1602), a calcitonin gene-related peptide receptor antagonist (CGRP-RA), for the acute treatment of migraine. Methods This double-blind, placebo-controlled study
Autor:
Jacky Smith, Eduardo Urdaneta, Ian D. Pavord, Alyn H. Morice, David Muccino, Lorcan McGarvey, Peter V. Dicpinigaitis, C. La Rosa, A. Birring, Christopher Assaid
Publikováno v:
Chest. 157:A4